Clinical Trials

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02586857 2026-03-25

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

CNSLymphoidOther hematologic neoplasm

24 enrolled 10 charts

Glioblastoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02717611 2026-03-25

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

60 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02180724 2026-03-20

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

29 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

124 enrolled 10 charts 2 FDA

Lymphoma, Mantle-Cell

NCT02029443 2026-02-06

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

306 enrolled 26 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03932331 2026-01-29

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05583149 2026-01-29

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

28 enrolled 6 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT04657094 2025-04-27

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Classical hematologyLymphoidOther hematologic neoplasm

4 enrolled 7 charts

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04783415 2024-12-02

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

12 enrolled 8 charts